Health News: Weight Loss

An Ally in weight loss Minneapolis-St. Paul Star Tribune Sat, 23 Jun 2007 10:35 PM PDT What is it? First FDA approved over-the-counter weight-loss pill. What's the claim? It will help you lose 50 percent more weight than dieting alone. How does it work? Blocks the body's absorption of 25 percent of dietary fat. Is it true? It can help, but you have to limit fatty foods. Are there health risks? It also blocks absorption of fat-soluble vitamins. Other problems? If you eat too much ... BYETTA? Treatment For Three And A Half Years Associated With Reductions In Cardiovascular Risk Factors In People With ... Medical News Today Sun, 24 Jun 2007 0:07 AM PDT Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced results from a study that showed BYETTA? (exenatide) injection sustained improvements in blood sugar levels and progressive weight loss through three and a half years of therapy. BYETTA treatment was also associated with improvements in cardiovascular risk factors in people with type 2 diabetes. ... Despite high hopes, diet pill brings questions, side effects Minneapolis-St. Paul Star Tribune Sat, 23 Jun 2007 8:35 PM PDT The little white bottle comes with a massive advertising campaign, a diet book and some alarming advice from the manufacturer: Carry an extra pair of pants, just in case. Alli, the only over-the-counter weight-loss drug to be approved by the Food and Drug Administration, has just hit drugstore shelves. It's a less potent version of Xenical, a prescription drug available since the mid-1970s that ... BYETTA(R) Treatment for Three and a Half Years Associated With Reductions in Cardiovascular Risk Factors in People With ... RedNova Sat, 23 Jun 2007 10:06 AM PDT CHICAGO, June 23 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from a study that showed BYETTA(R) (exenatide) injection sustained improvements in blood sugar levels and progressive weight loss through three and a half years of therapy. SYMLIN(R) Used in Conjunction with Basal Insulin in Patients with Type 2 Diabetes PR Newswire via Yahoo! Finance Sat, 23 Jun 2007 8:00 AM PDT Amylin Pharmaceuticals, Inc. announced today study results showing SYMLIN? injection used in conjunction with basal insulin improved glucose control and reduced weight without increased hypoglycemia in patients with type 2 diabetes inadequately controlled with insulin glargine and oral agents. Foie gras may transmit disease Los Angeles Times Sat, 23 Jun 2007 8:40 AM PDT Geese force-fed and then slaughtered for their livers may get their final revenge on people who favor the delicacy known as pate de foie gras: It may transmit a little-known disease known as amyloidosis, researchers reported Monday in the Proceedings of the National Academy of Sciences. Functional Analysis of PDX2 From Arabidopsis, a Glutaminase Involved in Vitamin B6 Biosynthesis1[W][OA] RedNova Sun, 24 Jun 2007 1:07 AM PDT By Tambasco-Studart, Marina Tews, Ivo; Amrhein, Nikolaus; Fitzpatrick, Teresa B Vitamin B6 is an essential metabolite in all organisms, being required as a cofactor for a wide variety of biochemical reactions. More local patients struggle to get health care The Olympian Sat, 23 Jun 2007 11:18 PM PDT Yvette Perrine?s blood pressure was up, and she needed to see a doctor, but she doesn?t have health insurance. Diet Pill Sells in Debut Despite Its Side Effects RedNova Sat, 23 Jun 2007 6:07 PM PDT By Ann Tatko-Peterson, Contra Costa Times, Walnut Creek, Calif. Jun. 23--Only one package of alli, the new diet drug, remained Thursday morning at Long's Drugs in Moraga. Orexigen(TM) Therapeutics Reports Contrave(TM) Has Positive Effect on Visceral Fat and Insulin Resistance, Factors ... RedNova Sat, 23 Jun 2007 10:10 AM PDT SAN DIEGO and CHICAGO, June 23 /PRNewswire-FirstCall/ -- Orexigen(TM) Therapeutics, Inc.